Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 629Prostatic Neoplasms 372Neoplasms 304Carcinoma, Non-Small-Cell Lung 216Lung Neoplasms 205Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 135Leukemia, Myeloid, Acute 129Neoplasm Metastasis 124Melanoma 116Brain Neoplasms 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 81Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × HER2-positive Metastatic Breast Cancer × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡